BRAFv600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma

被引:9
作者
Jing Fan-jing [1 ]
Liang Jun [1 ]
Liang Zhi-yong [2 ]
Meng Chao [1 ]
Long Wen [3 ]
Li Xiao-yi [4 ]
Lin Yan-song [3 ]
机构
[1] Qingdao Univ, Qingdao Med Coll, Affiliated Hosp, Dept Oncol, Qingdao 266003, Shandong, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Pathol, Beijing 100730, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Nucl Med, Beijing 100730, Peoples R China
[4] Peking Union Med Coll Hosp, Dept Gen Surg, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
papillary thyroid carcinoma; B-RAF; neoplasm metastasis; vascular endothelial growth factor; BRAF MUTATION; CLINICAL-IMPLICATIONS; PROGNOSTIC-FACTORS; CANCER; SURVIVAL; OUTCOMES; EPIDEMIOLOGY; VEGF;
D O I
10.3760/cma.j.issn.0366-6999.20122032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background BRAF(v600E) mutation is correlated with local aggressive clinicopathological features in papillary thyroid carcinoma; yet the relationship between this genetic variation and distant papillary thyroid carcinoma metastasis was unclear. This study aimed to investigate whether BRAF(v600E) is predictive for distant metastasis in the Chinese population. Methods One hundred and seven patients with papillary thyroid carcinoma were enrolled in this study, including 43 patients with distant metastasis and 64 patients without. Quantitative real-time polymerase chain reaction was used to detect BRAF(v600E) mutation, while immunohistochemistry was performed to detect vascular endothelial growth factor (VEGF) expression. The associations between distant metastasis and BRAF(v600E) mutation, and VEGF expression as well as local clinicopathological factors were determined. Results A total of 28.6% of the patients in the distant metastasis group harbored BRAF(v600E) mutation, which was significantly lower than in the without distant metastasis group (68.8%, P < 0.001). BRAF(v600E) mutation was negatively correlated with positive VEGF expression (P=0.001). Furthermore, 52.2% of the patients with distant metastasis exhibited VEGF expression, compared with 25.0% of those without. Higher levels of VEGF expression were also observed in the distant metastasis group. Tumor size, extra-thyroid invasion, and BRAF(v600E) mutation were independent predictors for distant metastasis according to multivariate analysis (odds ratios were 2.8, 12.4, and 0.3; 95% C/ 1.483-5.334, and 2.950-52.407, 0.100-0.890; P=0.002, 0.001, and 0.030, respectively). BRAF(v600E) mutation was negatively correlated with distant metastasis in adult subgroup analysis (P=0.005) but was not an independent parameter. Conclusions BRAF(v600E) mutation is predictive for distant metastasis in papillary thyroid carcinoma but not positively. VEGF may be involved in the pathogenesis of distant metastasis.
引用
收藏
页码:3013 / 3018
页数:6
相关论文
共 31 条
[1]   BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma [J].
Ahn, Dongbin ;
Park, June Sik ;
Sohn, Jin Ho ;
Kim, Jae Hyug ;
Park, Sun-Kyun ;
Seo, An Na ;
Park, Ji Young .
AURIS NASUS LARYNX, 2012, 39 (02) :198-203
[2]   Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood [J].
Bremnes, RM ;
Camps, C ;
Sirera, R .
LUNG CANCER, 2006, 51 (02) :143-158
[3]   Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer [J].
Chrisoulidou A. ;
Boudina M. ;
Tzemailas A. ;
Doumala E. ;
Iliadou P.K. ;
Patakiouta F. ;
Pazaitou-Panayiotou K. .
Thyroid Research, 4 (1)
[4]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[5]   Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry DISCUSSION [J].
Parangi, Sareh ;
Cramer, John D. ;
Prinz, Richard A. ;
Zeiger, Martha A. ;
Kebebew, Electron .
SURGERY, 2010, 148 (06) :1152-1153
[6]   BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas [J].
Durante, Cosimo ;
Tallini, Giovanni ;
Puxeddu, Efisio ;
Sponziello, Marialuisa ;
Moretti, Sonia ;
Ligorio, Claudia ;
Cavaliere, Antonio ;
Rhoden, Kerry J. ;
Verrienti, Antonella ;
Maranghi, Marianna ;
Giacomelli, Laura ;
Russo, Diego ;
Filetti, Sebastiano .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (03) :455-463
[7]  
Dzepina D., 2012, Int J Pediatr, V2012, P1253
[8]   BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:: A 15-year median follow-up study [J].
Elisei, Rossella ;
Ugolini, Clara ;
Viola, David ;
Lupi, Cristiana ;
Biagini, Agnese ;
Giannini, Riccardo ;
Romei, Cristina ;
Miccoli, Paolo ;
Pinchera, Aldo ;
Basolo, Fulvio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :3943-3949
[9]  
FRANCESCHI S, 1993, CRIT REV ONCOGENESIS, V4, P25
[10]  
Hansen TF, 2011, PHARMACOGENOMICS, V12, P1681, DOI [10.2217/pgs.11.118, 10.2217/PGS.11.118]